| Literature DB >> 20390108 |
Sherif S Ebada1, Wenhan Lin, Peter Proksch.
Abstract
Marine ecosystems (>70% of the planet's surface) comprise a continuous resource of immeasurable biological activities and immense chemical entities. This diversity has provided a unique source of chemical compounds with potential bioactivities that could lead to potential new drug candidates. Many marine-living organisms are soft bodied and/or sessile. Consequently, they have developed toxic secondary metabolites or obtained them from microorganisms to defend themselves against predators [1]. For the last 30-40 years, marine invertebrates have been an attractive research topic for scientists all over the world. A relatively small number of marine plants, animals and microbes have yielded more than 15,000 natural products including numerous compounds with potential pharmaceutical potential. Some of these have already been launched on the pharmaceutical market such as Prialt (ziconotide; potent analgesic) and Yondelis (trabectedin or ET-743; antitumor) while others have entered clinical trials, e.g., alpidin and kahalalide F. Amongst the vast array of marine natural products, the terpenoids are one of the more commonly reported and discovered to date. Sesterterpenoids (C(25)) and triterpenoids (C(30)) are of frequent occurrence, particularly in marine sponges, and they show prominent bioactivities. In this review, we survey sesterterpenoids and triterpenoids obtained from marine sponges and highlight their bioactivities.Entities:
Keywords: marine sponges; sesterterpenoids; triterpenoids
Mesh:
Substances:
Year: 2010 PMID: 20390108 PMCID: PMC2852841 DOI: 10.3390/md8020313
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Postulated biosynthetic relationship between all known Luffariella metabolites [12].
Figure 2Proposed biogenetic transformation of jaspolides A–F (108–113) [101].
Figure 3Postulated biogenetic pathway of jaspolides G (114) and H (115) [102].